

More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions

Ana-Maria Orbai, Serena Halls, Sarah Hewlett, Susan J. Bartlett, Amye L. Leong, Clifton O. Bingham III, and the RA Flare Group Steering Committee

ABSTRACT. Objective. Stiffness was endorsed within the rheumatoid arthritis (RA) flare core domain set at the previous Outcome Measures in Rheumatology meeting (OMERACT 11). Two stiffness breakout groups at the present OMERACT 12 RA flare workshop discussed results of new qualitative studies in RA stiffness.

Methods. Results from 2 independent studies of RA stiffness were presented to breakout group participants, followed by group discussions about stiffness measurement.

Results. Both studies identified stiffness as complex, variable with the level of disease activity, and as encompassing concepts of impact, intensity, timing, location, and duration. That stiffness has an effect on multiple dimensions of health was a common finding. Participants agreed that stiffness is an important aspect of RA flare. Whether measuring only morning stiffness duration, the traditional approach in RA, was sufficient in coverage of the concept was unclear. Groups agreed that more research on stiffness measurement is needed considering the importance patients place on the effect of stiffness.

Conclusion. Results from independent studies highlight stiffness effect as an important feature of RA, in addition to intensity, timing, location, and duration. Additional work is needed to identify optimal ways to assess stiffness in RA and other rheumatologic diseases. (J Rheumatol First Release March 1 2015; doi:10.3899/jrheum.141172)

Key Indexing Terms:

OMERACT

RHEUMATOID ARTHRITIS

STIFFNESS

FLARE

From Johns Hopkins University, Baltimore, Maryland, USA; University of the West of England, Bristol, UK; McGill University, Montreal, Quebec, Canada; Healthy Motivation, Santa Barbara, California, USA; Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany; Hospital for Special Surgery, New York, New York, USA; Cardiff University, Cardiff, Wales, UK; Musculoskeletal Statistics Unit, Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark; UCLA Medical School, Los Angeles, California, USA; University of Sydney, Sydney, Australia; Leading Edge Clinical Research, Stuart, Florida, USA.

Supported by the Ira Fine Discovery Fund, Donald and Dorothy Stabler Foundation, Sibley Memorial Hospital Foundation, Johns Hopkins Arthritis Center Research Fund, National Institutes of Health P30-AR053503; COB is supported in part by US National Institutes of Health/US National Institute of Arthritis and Musculoskeletal and Skin Diseases P30-AR053503 and a Pilot Project award from the Patient Centered Outcomes Research Institute. AO is supported by the Scientist Development Award from the Rheumatology Research Foundation. COB is an executive member of OMERACT, an organization that develops and validates outcome measures. OMERACT receives arms-length funding from 23 pharmaceutical and clinical research companies.

A.M. Orbai, MD, MHS, Johns Hopkins University; S. Halls, PhD candidate; S. Hewlett, FRCN, PhD, MA, RN, University of the West of England; S.J. Bartlett, PhD, Johns Hopkins University and McGill University; A.L. Leong, MBA, Healthy Motivation; C.O. Bingham III, MD, Johns Hopkins University; and the RA Flare Group Steering Committee (see Appendix 1).

Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu

Based on progress made at previous OMERACT meetings^{1,2,3}, a rheumatoid arthritis (RA) flare core domain set was proposed and endorsed at OMERACT 11 to measure symptoms and effects representing disease worsening of sufficient intensity and duration to require consideration of (re)initiation, change, or increase in therapy⁴. Identifying appropriate methods to measure each domain has been the focus of OMERACT RA Flare Group research over the past 2 years^{5,6}.

There are multiple ways for assessing stiffness in RA. Most often in randomized clinical trials (RCT), patients indicate the duration of morning stiffness^{7,8}, but stiffness intensity has also been used⁹. Measures of stiffness have not been consistently linked to therapeutic response in RCT^{8,9,10}. The overall concept of stiffness in RA remains poorly defined. It is unclear whether assessing morning stiffness duration and intensity adequately reflects the heterogeneity of the construct^{11,12}.

During the RA flare workshop held at OMERACT 12, 2 breakout groups reviewed new qualitative findings of RA stiffness and discussed whether a new measurement approach may be needed. Qualitative study results are particularly relevant to ensure that the content of measures adequately

Circle the number that best describes the stiffness you have felt due to your rheumatoid arthritis during the past week:



Figure 1. Stiffness intensity visual analog scale from a preliminary flare questionnaire.

reflects the concept being measured in patient-reported outcomes^{13,14}.

METHODS

During the OMERACT 12 RA flare workshop plenary, stiffness data were compared between patients with RA in flare versus those not in flare in 2 longitudinal observational studies (LOS) and 1 RCT (unpublished data). The stiffness question, developed by the Flare Steering Committee, asked people to “Circle the number that best describes the stiffness you have felt due to your rheumatoid arthritis during the past week” (0–10 numeric rating scale where 0 = none and 10 = extreme; Figure 1). Two breakout groups were held to discuss these results and new qualitative studies conducted in the United States and United Kingdom^{11,12} in relation to stiffness measurement.

RESULTS

Qualitative Studies

Results from 2 independent qualitative studies of stiffness in people with RA conducted independently were presented to both groups in a common 10-min session^{11,12}. The US study comprised 4 focus groups with 20 patients; the UK study included one-on-one interviews with 16 patients.

In both studies, patients described stiffness as a common RA feature, which varied within and among individuals and with levels of RA disease activity — results consistent with our earlier foundational qualitative studies and Delphi exercises on RA flares^{15,16}. Changes in stiffness were often associated with changes in other symptoms, especially pain. Many people reported stiffness that was not limited to the morning, but occurred at various times or throughout the entire day. Further, stiffness was not always limited to specific joints, but could vary in location. Exacerbating factors included weather and immobility, and alleviating factors and self-management strategies were described, also consistent with earlier work for multiple RA flare symptoms^{3,16,17}. Of note, in both studies participants described stiffness most often in terms of its effect on day-to-day life activities, including getting dressed, driving, cooking, and attending (or not) a social event. This is in line with prior OMERACT work that emphasized the importance of evaluating symptom effect, rather than just symptom amount or severity¹⁸.

Breakout Group Discussions

The two parallel groups (n = 20 and n = 16) discussed quantitative and qualitative results. Although in the plenary, data from RCT and LOS showed that stiffness intensity was clinically and statistically higher in flaring patients versus those

not in flare, there was uncertainty in both groups whether only measuring intensity adequately characterizes stiffness across individuals and with varying levels of disease activity. Similarly, the usefulness of querying only duration of morning stiffness in RCT was also questioned, but no consensus was achieved.

There was general agreement that further research needed to identify an optimal approach to measuring relevant aspects of stiffness in RA (e.g., duration, intensity, impact) should incorporate terms patients use (e.g., restricted movement, joint tightness) to describe stiffness. There was also recognition that stiffness is a feature of several rheumatic conditions (polymyalgia rheumatica, ankylosing spondylitis, psoriatic arthritis, and osteoarthritis), and there is value in exploring common aspects of stiffness across diseases. Finally, there was endorsement of interest in creating an OMERACT Stiffness special interest group to coordinate further research across conditions.

DISCUSSION

Qualitative and quantitative studies have confirmed that stiffness is an important symptom experienced by most patients with RA^{2,15,16}; moreover, stiffness was included in the RA Flare Core Domain Set ratified at OMERACT 11^{3,4,16}. Two qualitative studies were conducted by members of our group to further explore the experience of stiffness in RA^{11,12}. Similar themes were identified in both studies and incorporated into conceptual frameworks encompassing the heterogeneous experience of stiffness impact, intensity, timing, location and duration in people with RA. Moreover, stiffness could independently affect physical, emotional, and social health, distinct from other RA symptoms. The measurement of stiffness is challenging because of the complexity of the experience and narrow focus of existing measures. The extent to which there is overlap among the different stiffness dimensions (duration, intensity, impact, location, timing) requires additional study. Key areas that remain unclear include: Is morning stiffness duration a proxy for intensity? Does a measure of stiffness effect provide additional explanatory information beyond intensity and/or duration? Other aspects of stiffness that require additional examination: Does the relative importance of stiffness vary according to overall levels of disease activity? Is there a difference in importance or magnitude for stiffness in disease worsening vs improvement? Answering these questions is necessary to determine how many aspects must be measured

to adequately reflect the construct in RA in different contexts (e.g., RCT vs LOS, different RCT study designs).

A growing body of evidence suggests that additional work may be needed to better characterize and measure stiffness in RA and other rheumatic diseases. While people who are experiencing an RA flare report significantly higher levels of stiffness, other factors such as effect on quality of life, timing, location, and duration may also be important. A new OMERACT special interest group would be well positioned to develop this research agenda and identify optimal ways to measure stiffness in RA and other rheumatic diseases.

APPENDIX 1

List of study collaborators. OMERACT RA Flare Group Steering Committee Members: Rieke Alten, Schlosspark-Klinik, University Medicine Berlin, Germany; Susan J. Bartlett, Johns Hopkins University, Baltimore, MD, USA, and McGill University, Montreal, Canada; Clifton O. Bingham 3rd, Johns Hopkins University, Baltimore, MD, USA; Vivian P. Bykerk, Hospital for Special Surgery, New York, NY, USA; Ernest H. Choy, Cardiff University, Cardiff, UK; Robin Christensen, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark; Daniel E. Furst, UCLA Medical School, Los Angeles, CA, USA; Sarah Hewlett, University of the West of England, Bristol, UK; Amye L. Leong, Healthy Motivation, Santa Barbara, CA, USA; Lyn March, University of Sydney, Sydney, Australia; Thasia G. Woodworth, Leading Edge Clinical Research, Stuart, FL, USA.

REFERENCES

1. Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. *J Rheumatol* 2011;38:1745-50.
2. Bingham CO 3rd, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. *J Rheumatol* 2011;38:1751-8.
3. Bingham CO 3rd, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, et al. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). *J Rheumatol* 2009;36:2335-41.
4. Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. *J Rheumatol* 2014;41:799-809.
5. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol* 2014;67:745-53.
6. Boers M, Kirwan JR, Gossec L, Conaghan PG, D'Agostino MA, Bingham CO 3rd, et al. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. *J Rheumatol* 2014;41:1025-30.
7. Kalyoncu U, Dougados M, Daurès JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis* 2009;68:183-90.
8. Buttgerieit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. *Lancet* 2008;371:205-14.
9. Buttgerieit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). *Ann Rheum Dis* 2013;72:204-10.
10. Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. *Arthritis Rheum* 1995;38:1568-80.
11. Orbai AM, Smith KC, Bartlett SJ, De Leon E, Bingham CO, 3rd. "Stiffness has different meanings, I think, to everyone": examining stiffness from the perspective of people living with rheumatoid arthritis. *Arthritis Care Res* 2014;66:1662-72.
12. Halls S, Dures E, Kirwan J, Pollock J, Baker G, Edmunds A, et al. Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. *Rheumatology* 2014 Sep 16 (E-pub ahead of print).
13. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1—eliciting concepts for a new PRO instrument. *Value Health* 2011;14:967-77.
14. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. *Value Health* 2011;14:978-88.
15. Hewlett S, Sanderson T, May J, Alten R, Bingham CO, 3rd, Cross M, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. *Rheumatology* 2012;51:69-76.
16. Bartlett SJ, Hewlett S, Bingham CO, 3rd, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. *Ann Rheum Dis* 2012;71:1855-60.
17. Flurey CA, Morris M, Richards P, Hughes R, Hewlett S. It's like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes. *Rheumatology* 2014;53:696-703.
18. Sanderson TC, Hewlett SE, Flurey C, Dures E, Richards P, Kirwan JR. The impact triad (severity, importance, self-management) as a method of enhancing measurement of personal life impact of rheumatic diseases. *J Rheumatol* 2011;38:191-4.